View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Korányi Sándor u. 2/A, 1083
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
  • 3 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
  • 4 Országos Gerincgyógyászati Központ, Budapest

Absztrakt

Bevezetés: Az 1,25-dihidroxi-D3-vitamin tumorellenes hatása hepatocellularis carcinomában már részben ismert. Célkitűzés: Az 1,25-dihidroxi-D3-vitamint inaktiváló CYP24A1-mRNS- és fehérjeexpresszió, az aktiváló CYP27B1- és a VDR-mRNS-expresszió mértékének összehasonlítása humán hepatocellularis carcinomában és az azt körülvevő tumormentes májszövetben. Módszer: 13 beteg friss fagyasztott májszövetmintáját a CYP24A1-mRNS- és fehérje-, 36 beteg paraffinba ágyazott májszövetmintáját használtuk a VDR- és a CYP27B1-mRNS-expresszió kimutatására. Az mRNS-expressziót RT-PCR-rel, a fehérjét immunhisztokémiai vizsgálatokkal mértük. Eredmények: A hepatocellularis carcinomaminták többségében kimutatható volt a CYP24A1-mRNS-expresszió, míg a nem tumoros májszövetminták egyikében sem. A CYP27B1- és VDR-expresszió szignifikánsan alacsonyabb hepatocellularis carcinomában a tumormentes májszövethez képest (p<0,05). A CYP24A1-mRNS-expressziót fehérjeszintézis követi. Következtetések: A CYP24A1 inaktiváló enzim jelenléte, az aktiváló CYP27B1 és a VDR csökkent expressziója humán hepatocellularis carcinomában a D-vitamin csökkent helyi aktivitására enged következtetni, mint egy menekülő mechanizmus a tumor részéről a D-vitamin antitumorhatása ellen. Orv. Hetil., 2016, 157(48), 1910–1918.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    El-Serag, H. B., Rudolph, K. L.: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132(7), 2557–2576.

  • 2

    http://www.onkol.hu/hu/rakregiszter-statisztika

  • 3

    Bosetti, C., Turati, F., La Vecchia, C.: Hepatocellular carcinoma epidemiology. Best Pract. Res. Clin. Gastroenterol., 2014, 28(5), 753–770.

  • 4

    Hu, K. Q., Tong, M. J.: The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatolology, 1999, 29(4), 1311–1316.

  • 5

    Serfaty, L., Aumaître, H., Chazouillères, O., et al.: Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology, 1998, 27(5), 1435–1440.

  • 6

    Deeb, K. K., Trump, D. L., Johnson, C. S.: Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer, 2007, 7(9), 684–700.

  • 7

    Welsh, J.: Vitamin D metabolism in mammary gland and breast cancer. Mol. Cell. Endocrinol., 2011, 347(1–2), 55–60.

  • 8

    Giovannucci, E.: Epidemiology of vitamin D and colorectal cancer. Anticancer Agents Med. Chem., 2013, 13(1), 11–19.

  • 9

    Shui, I. M., Mucci, L. A., Kraft, P.: Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J. Natl. Cancer Inst., 2012, 104(9), 690–699.

  • 10

    Reddy, K. K.: Vitamin D level and basal cell carcinoma, squamous cell carcinoma, and melanoma risk. J. Invest. Dermatol., 2013, 133(3), 589–592.

  • 11

    Köstner, K., Denzer, N., Müller, C. S., et al.: The relevance of vitamin D receptor (VDR.) gene polymorphisms for cancer: a review of the literature. Anticancer Res., 2009, 29(9), 3511–3536.

  • 12

    Köstner, K., Denzer, N., Koreng, M., et al.: Association of genetic variants of the vitamin D receptor (VDR) with cutaneous squamous cell carcinomas (SCC) and basal cell carcinomas (BCC): a pilot study in a German population. Anticancer Res., 2012, 32(1), 327–333.

  • 13

    Falleti, E., Bitetto, D., Fabris, C., et al.: Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J. Gastroenterol., 2010, 16(24), 3016–3024.

  • 14

    Guo, J., Ma, Z., Ma, Q., et al.: 1,25(OH)2D3₃ inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes. Curr. Med. Chem., 2013, 20(33), 4131–4141.

  • 15

    Moore, D. D., Kato, S., Xie, W., et al.: The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol. Rev., 2006, 58(4), 742–759.

  • 16

    Goupil, D., Ethier, C., Zarnegar, R., et al.: Hepatic expression of regeneration marker genes following partial hepatectomy in the rat. Influence of 1,25-dihydroxyvitamin D3 in hypocalcemia. J. Hepatol., 1997, 26(3), 659–668.

  • 17

    Dalhoff, K., Dancey, J., Astrup, L., et al.: A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer, 2003, 89(2), 252–257.

  • 18

    Prosser, D. E., Jones, G.: Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci., 2004, 29(12), 664–673.

  • 19

    Fraser, D. R., Kodicek, E.: Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature, 1970, 228(5273), 764–766.

  • 20

    Holick, M. F.: 25-OH-vitamin D assays. J. Clin. Endocrinol. Metab., 2004, 90(5), 3128–3129.

  • 21

    Cheng, J. B., Levine, M. A., Bell, N. H., et al.: Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl Acad. Sci., 2004, 101(20), 7711–7715.

  • 22

    Pourgholami, M. H., Akhter, J., Finlay, I. G., et al.: 1,25-dihydroxyvitamin D3 dissolved in lipiodol produces a sustained antiproliferative effect in the human hepatoblastoma cell line HepG2. Anticancer Res., 2000, 20(2A), 723–727.

  • 23

    Ghous, Z., Akhter, J., Pourgholami, M. H., et al.: Inhibition of hepatocellular cancer by EB1089: in vitro and in vivo study. Anticancer Res., 2008, 28(6A), 3757–3761.

  • 24

    Colombo, M., Sangiovanni, A.: Vitamin D deficiency and liver cancer: more than just an epidemiological association? Hepatol., 2014, 60(4), 1130–1132.

  • 25

    Fedirko, V., Duarte-Salles, T., Bamia, C., et al.: Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study. Hepatology, 2014, 60(4), 1222–1230.

  • 26

    Huang, J., Yang, G., Huang, Y., et al.: 1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1). Mol. Med. Rep., 2016, 13(2), 1373–1380.

  • 27

    Pourgholami, M. H., Morris, D. L.: 1,25-dihydroxyvitamin D3 in lipiodol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies. J. Steroid Biochem. Mol. Biol., 2004, 89–90(1–5), 513–518.

  • 28

    Lopes, N., Sousa, B., Martins, D., et al.: Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer, 2010, 10, 483.

  • 29

    Hendrickson, W. K., Flavin, R., Kasperzyk, J. L., et al.: Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J. Clin. Oncol., 2011, 29(17), 2378–2385.

  • 30

    Clinckspoor, I., Hauben, E., Verlinden, L., et al.: Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors. J. Histochem. Cytochem., 2012, 60(7), 502–511.

  • 31

    Lointier, P., Meggouh, F., Dechelotte, P., et al.: 1,25-dihydroxyvitamin D3 receptors and human colon adenocarcinoma. Br. J. Surg., 1991, 78(4), 735–739.

  • 32

    Matusiak, D., Murillo, G., Carroll, R. E., et al.: Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiol. Biomarkers Prev., 2005, 14(10), 2370–2376.

  • 33

    Gascon-Barré, M., Demers, C., Mirshahi, A., et al.: The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology, 2003, 37(5), 1034–1042.

  • 34

    Miyaguchi, S., Watanabe, T.: The role of vitamin D3 receptor mRNA in the proliferation of hepatocellular carcinoma. Hepatogastroenterology, 2000, 47(32), 468–472.

  • 35

    Han, S., Chiang, J. Y.: Mechanism of vitamin D receptor inhibition of cholesterol 7-alpha-hydroxylase gene transcription in human hepatocytes. Drug Metab. Dispos., 2009, 37(3), 469–478.

  • 36

    Han, S., Li, T., Ellis, E., et al.: A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol. Endocrinol., 2010, 24(6), 1151–1164.

  • 37

    Gascon-Barré, M., Gamache, M.: Contribution of the biliary pathway to the homeostasis of vitamin D3 and of 1,25-dihydroxyvitamin D3. Endocrinology, 1991, 129(5), 2335–2344.

  • 38

    He, R. K., Gascon-Barré, M.: Influence of the vitamin D status on the early hepatic response to carcinogen exposure in rats. J. Pharmacol. Exp. Ther., 1997, 281(1), 464–469.

  • 39

    Segura, C., Alonso, M., Fraga, C., et al.: Vitamin D receptor ontogenesis in rat liver. Histochem. Cell Biol., 1999, 112(2), 163–167.

  • 40

    Mohri, T., Nakajima, M., Takagi, S., et al.: MicroRNA regulates human vitamin D receptor. Int. J. Cancer, 2009, 125(6), 1328–1333.

  • 41

    Anderson, M. G., Nakane, M., Ruan, X., et al.: Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol., 2005, 57(2), 234–240.

  • 42

    Horváth, H. C., Lakatos, P., Kósa, J. P., et al.: The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J. Histochem. Cytochem., 2010, 58(3), 277–285.

  • 43

    Hendrickson, W. K., Flavin, R., Kasperzyk, J. L., et al.: Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J. Clin. Oncol., 2011, 29(17), 2378–2385.

  • 44

    Trowbridge, R., Sharma, P., Hunter, J. W., et al.: Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma. Exp. Mol. Pathol., 2012, 93(1), 147–153.

  • 45

    Yang, M. H., Chen, C. L., Chau, G. Y., et al.: Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology, 2009, 50(5), 1464–1474.

  • 46

    Li, Q., Gao, Y., Jia, Z., et al.: Dysregulated Krüppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. Gastroenterology, 2012, 143(3), 799–810.

  • 47

    Zinser, G. M., McEleney, K., Welsh, J.: Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Mol. Cell. Endocrinol., 2003, 200(1–2), 67–80.

  • 48

    Swami, S., Krishnan, A. V., Feldman, D.: 1-alpha,25-dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin. Cancer Res., 2000, 6(8), 3371–3379.

  • 49

    Stoica, A., Saceda, M., Fakhro, A., et al.: Regulation of estrogen receptor-alpha gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells. J. Cell. Biochem., 1999, 75(4), 640–651.

  • 50

    Canalejo, A., Canalejo, R., Rodriguez, M. E., et al.: Development of parathyroid gland hyperplasia without uremia: role of dietary calcium and phosphate. Nephrol. Dial. Transplant., 2010, 25(4), 1087–1097.

  • 51

    Chiang, K. C., Yen, C. L, Yeh, C. N., et al.: Hepatocellular carcinoma cells express 25(OH)D-1α-hydroxylase and are able to convert 25(OH)D to 1α,25(OH)2D, leading to the 25(OH)D-induced growth inhibition. J. Steroid Biochem. Mol. Biol., 2015, 154, 47–52.

  • 52

    Balla, B., Kósa, J. P., Tobiás, B., et al.: Marked increase in CYP24A1 gene expression in human papillary thyroid cancer. Thyroid, 2011, 21(4), 459–460.

  • 53

    Mimori, K., Tanaka, Y., Yoshinaga, K., et al.: Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann. Oncol., 2004, 15(2), 236–241.

  • 54

    Chen, G., Kim, S. H., King, A. N., et al.: CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin. Cancer Res., 2011, 17(4), 817–826.

  • 55

    Kennedy, L., Baker, K., Hodges, K., et al.: Dysregulation of vitamin D3 synthesis leads to enhanced cholangiocarcinoma growth. Dig. Liv. Dis., 2013, 45(4), 316–322.

  • 56

    Gal-Tanamy, M., Bachmetov, L., Ravid, A., et al.: Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology, 2011, 54(5), 1570–1579.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Oct 2020 0 4 0
Nov 2020 0 14 3
Dec 2020 0 5 2
Jan 2021 0 8 3
Feb 2021 0 11 11
Mar 2021 0 7 0
Apr 2021 0 2 1